Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Calidi Biotherapeutics (CLDI) has shared an announcement.
The Company has announced a reverse stock split of its common stock at a 1-for-10 ratio, aimed at consolidating shares and possibly boosting the stock price. This strategic move, detailed in a recent press release, is significant information for investors though it’s specified not to have any legal implications for the company’s filings or liabilities under the Securities Exchange Act.
Learn more about CLDI stock on TipRanks’ Stock Analysis page.